If, on the other hand, patients with malignant astrocytomas and an IDH mutation are examined, there is still a difference between patients with necrosis and/or vascular proliferation and those whose tumors do not show such characteristics. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).